BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GRN1005: Phase II started

Geron began the open-label, U.S. Phase II GRABM-B trial to evaluate 650 mg/m 2 IV GRN1005 once every 3 weeks in about 100 patients with brain metastases from mBC. Patients with HER2-negative mBC will receive GRN1005 alone, while those with HER2-positive...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >